When will serputinib/serpatinib enter the Chinese market?

Selpercatinib/Selpercatinib has been approved for marketing by the National Medical Products Administration on September 30, 2022, which means that Selpercatinib can already be sold and used in the Chinese market and be used to treat patients who meet its indications. The specific supply situation of a drug after it is launched may be affected by a variety of factors, such as pricing, market demand, etc. Therefore, although the drug has been approved for marketing, exactly when and where it will be available may need to be determined on a case-by-case basis.

Seputinib is a highly selective receptor tyrosine kinase RET (rearrangement during transfection) inhibitor used to treat a variety of solid tumors, including non-small cell lung cancer (NSCLC) and thyroid cancer. Aberrantly activated RET can serve as an oncogene in a variety of cancers; RET fusions retaining the kinase domain are drivers of non-small cell lung cancer and papillary thyroid carcinoma, and activating RET mutations are associated with different phenotypes in multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma (MTC).

Up to now, the original research drug is sold in China under the name of Seputinib, but it is not included in medical insurance. The price of each box of 80mg*56 tablets may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).